# A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

> **NCT02146651** · PHASE2 · COMPLETED · sponsor: **Adocia** · enrollment: 38 (actual)

## Conditions studied

- Diabetes Mellitus Type 1

## Interventions

- **DRUG:** BioChaperone insulin lispro 0.2U/Kg
- **DRUG:** BioChaperone insulin lispro 0.1U/Kg
- **DRUG:** BioChaperone insulin lispro 0.4U/Kg
- **DRUG:** Humalog®

## Key facts

- **NCT ID:** NCT02146651
- **Lead sponsor:** Adocia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02146651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02146651, "A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02146651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*